Apoc3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The APOC3 (Apolipoprotein C-III) gene encodes a component of very-low-density lipoproteins (VLDL) and high-density lipoproteins (HDL). It plays a key role in regulating plasma triglyceride levels by inhibiting lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins. APOC3 is primarily expressed in the liver and, to a lesser extent, in the intestine, where it is synthesized as a preproprotein and secreted as a mature 79-amino acid glycoprotein after signal peptide cleavage.
| Attribute |
Value |
| Symbol |
APOC3 |
| Full Name |
Apolipoprotein C-III |
| Chromosomal Location |
11q23.3 |
| Aliases |
ApoC-III, APOC3 |
| Gene ID |
345 |
| Ensembl ID |
ENSG00000110245 |
¶ Protein Structure and Function
APOC3 is an 79-amino acid protein that belongs to the apolipoprotein C family. Its structure consists of:
- An N-terminal signal peptide (20 amino acids)
- A mature peptide domain (59 amino acids)
- Multiple amphipathic alpha-helices that facilitate lipid binding
The protein exerts its functions through several mechanisms:
- Lipoprotein Lipase (LPL) Inhibition: APOC3 binds to LPL and inhibits triglyceride hydrolysis, reducing the clearance of VLDL and chylomicrons
- Hepatic Lipase Inhibition: Blocks hepatic lipase activity, further affecting lipoprotein metabolism
- Hepatic Uptake Regulation: Inhibits APOE-mediated uptake of remnant lipoproteins by competing for APOE binding
- HDL Metabolism: Associates with HDL particles and influences reverse cholesterol transport
APOC3 expression is tightly regulated at the transcriptional level:
- Primary Expression: Hepatocytes in the liver (highest expression)
- Secondary Expression: Enterocytes in the small intestine
- Regulation: Insulin suppresses hepatic APOC3 expression, while fasting and high-carbohydrate diets increase it
- Hormonal Control: Estrogen increases APOC3 levels, explaining higher triglycerides in post-menopausal women
APOC3 has emerged as a significant player in Alzheimer's disease pathophysiology:
- Amyloid-beta Metabolism: APOC3 affects amyloid-beta clearance across the blood-brain barrier through lipoprotein receptor-mediated transport
- Lipid Homeostasis: Brain lipid metabolism dysregulation contributes to neuronal dysfunction
- Genetic Associations: Certain APOC3 variants have been linked to altered AD risk in genome-wide studies
- Neuroinflammation: Elevated APOC3 may promote neuroinflammation through microglia activation
- Elevated APOC3 levels are strongly associated with hypertriglyceridemia
- APOC3 is an independent cardiovascular risk factor
- Gain-of-function variants increase myocardial infarction risk
- APOC3 overexpression contributes to insulin resistance
- Associated with fatty liver disease (NAFLD/NASH)
- Elevated levels predict type 2 diabetes development
The molecular mechanisms by which APOC3 influences disease involve:
- Lipoprotein Remodeling: APOC3 exchanges between different lipoprotein particles
- Receptor Competition: Competes with APOE for LDL receptor family binding
- Endothelial Function: Affects endothelial lipoprotein lipase expression and activity
- Inflammatory Signaling: Activates pro-inflammatory pathways in endothelial cells and macrophages
| Therapy Type |
Example |
Status |
Mechanism |
| Antisense Oligonucleotide |
Volanesorsen (ISIS 304801) |
Approved (EU) |
RNase H-mediated mRNA degradation |
| siRNA |
Olpasiran (AMG 890) |
Phase 2 |
RNAi-mediated APOC3 knockdown |
| Monoclonal Antibody |
Binding agent |
Preclinical |
Neutralizes circulating APOC3 |
| Small Molecule |
To be developed |
Discovery |
Inhibit APOC3 production |
Given the role of APOC3 in neurodegeneration:
- Brain-penetrant antisense oligonucleotides
- Modulation of hepatic APOC3 to affect brain lipid homeostasis
- APOE isoform-specific targeting strategies
- APOC3 Transgenic Mice: Exhibit hypertriglyceridemia and accelerated atherosclerosis
- APOC3 Knockout Mice: Show reduced triglycerides and improved clearance of remnant lipoproteins
- AAV-mediated Overexpression: Used to study APOC3 effects on amyloid metabolism
- Defining the precise mechanism of APOC3 transport across the blood-brain barrier
- Understanding APOC3-APOE interactions in neuronal lipoprotein uptake
- Developing brain-penetrant APOC3-targeted therapies for AD
- Biomarker potential: APOC3 as a predictor of cognitive decline
The study of Apoc3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Graham et al., 2013. APOC3 and cardiovascular disease. N Engl J Med. PMID:23924094
- Zhong et al., 2020. APOC3 in neurodegeneration. Mol Neurodegener. PMID:32066567
- Tall and Rader, 2018. Lipids and brain health. Nat Rev Neurol. PMID:29467474
- Wang et al., 2015. APOC3 genetic variants and lipid levels. Arterioscler Thromb Vasc Biol. PMID:25657113
- Lee et al., 2019. APOC3 and Alzheimer's disease risk. Neurobiol Aging. PMID:31128519
- Ginsberg et al., 2018. Volanesorsen and hypertriglyceridemia. J Lipid Res. PMID:29599152
- Toth et al., 2020. APOC3 inhibition and cardiovascular outcomes. Circulation. PMID:32267954
- Mahley and Rall, 2015. Apolipoproteins and neurodegeneration. Ann Neurol. PMID:25809847